PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33370992-0	2020	Mycophenolate mofetil-induced liver injury in a patient with aquaporin-4 antibody positive transverse myelitis.	Mycophenolic Acid	0-21	aquaporin 4	Homo sapiens	61-72	
34797551-14	2022	CONCLUSIONS: RTX, AZA, and MMF therapies efficiently lowered the relapse frequency and disability in both of the AQP4-Ab seropositive or seronegative patients with NMO.	Mycophenolic Acid	27-30	aquaporin 4	Homo sapiens	113-117	
35398950-12	2022	CONCLUSION: We provide Class III evidence that reduced dose of RTX is superior to AZA and MMF as initial treatment to reduce the risk of relapse and is better tolerated than AZA in Chinese patients with AQP4-antibody-positive NMOSD.	Mycophenolic Acid	90-93	aquaporin 4	Homo sapiens	203-207	
33370992-1	2020	We present a case of a 49-year-old woman diagnosed with aquaporin-4 antibody-positive transverse myelitis, who developed a significant transaminitis 2 months after commencing mycophenolate mofetil (MMF) as a steroid-sparing agent.	Mycophenolic Acid	175-196	aquaporin 4	Homo sapiens	56-67	
33370992-1	2020	We present a case of a 49-year-old woman diagnosed with aquaporin-4 antibody-positive transverse myelitis, who developed a significant transaminitis 2 months after commencing mycophenolate mofetil (MMF) as a steroid-sparing agent.	Mycophenolic Acid	198-201	aquaporin 4	Homo sapiens	56-67	
27885065-0	2017	Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders.	Mycophenolic Acid	17-38	aquaporin 4	Homo sapiens	64-68